Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice

被引:20
作者
Sakai, T [1 ]
Hisaeda, H
Nakano, Y
Zhang, MX
Takashima, M
Ishii, K
Maekawa, Y
Matsumoto, S
Nitta, Y
Miyazaki, J
Yamamoto, S
Himeno, K
机构
[1] Univ Tokushima, Sch Med, Dept Parasitol & Immunol, Tokushima 7708503, Japan
[2] Univ Tokushima, Sch Med, Dept Nutr, Tokushima 7708503, Japan
[3] Kyushu Univ, Grad Sch Med, Dept Parasitol & Immunol, Kyushu 8128582, Japan
[4] Nagasaki Univ, Sch Dent, Nagasaki 8528523, Japan
[5] Osaka Univ, Grad Sch Med, Dept Nutr & Physiol Chem, Osaka 5650871, Japan
关键词
merozoite surface protein-1; DNA vaccine; interleukine-12;
D O I
10.1016/S0264-410X(02)00665-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The carboxyl-terminal region of the merozoite surface protein-1 (MSPI) is a leading candidate for a vaccine against malaria in the erythrocytic stage. In this study, we investigated the utility of interleukin-12 (IL-12) cDNA as an adjuvant for malaria DNA vaccine in a mouse challenge model. We found that co-immunization of expression plasmids encoding a C-terminal 15-kDa fragment of MSPI (MSP1-15) with the IL-12 gene using a gene gun significantly increased the protective immunity against malaria as compared with MSP1-15 DNA immunization alone. Co-immunization of IL-12 DNA potentiated MSP1-15-specific T helper (Th)1-type immune responses as evaluated by in vivo antibody (Ab) responses and in vitro cytokine profiles. After the Plasmodium yoelii challenge, mice immunized with MSP1-15 plus IL-12 DNA showed a higher level of interferon gamma (IFN-gamma) production than did other groups of mice. In vivo neutralization of IFN-gamma or depletion of CD4(+) T cells completely abolished this protective immunity. Macrophages, but not nitric oxide (NO), were found to play an important role in this effector mechanism. The sera from mice in which the infection had been cleared by the vaccination showed strong protection against P. yoelii infection. Thus, in addition to cellular immune responses, Abs against parasites induced in the course of infection are essential for protection against P. yoelii. The results indicate that combined vaccination with DNA encoding antigenic peptides plus IL-12 DNA provides a strategy for improving the prophylactic efficacy of a vaccine for malaria infection. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1432 / 1444
页数:13
相关论文
共 60 条
[11]  
Doolan DL, 1999, J IMMUNOL, V163, P884
[12]   Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8(+) T cell-, interferon gamma-, and nitric oxide-dependent immunity [J].
Doolan, DL ;
Sedegah, M ;
Hedstrom, RC ;
Hobart, P ;
Charoenvit, Y ;
Hoffman, SL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) :1739-1746
[13]   ABILITY OF RECOMBINANT OR NATIVE PROTEINS TO PROTECT MONKEYS AGAINST HETEROLOGOUS CHALLENGE WITH PLASMODIUM-FALCIPARUM [J].
ETLINGER, HM ;
CASPERS, P ;
MATILE, H ;
SCHOENFELD, HJ ;
STUEBER, D ;
TAKACS, B .
INFECTION AND IMMUNITY, 1991, 59 (10) :3498-3503
[14]   CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M-tuberculosis [J].
Freidag, BL ;
Melton, GB ;
Collins, F ;
Klinman, DM ;
Cheever, A ;
Stobie, L ;
Suen, W ;
Seder, RA .
INFECTION AND IMMUNITY, 2000, 68 (05) :2948-2953
[15]  
Gabaglia CR, 1999, J IMMUNOL, V162, P753
[16]   High oxygen radical production ts associated with fast parasite clearance in children with Plasmodium falciparum malaria [J].
Greve, B ;
Lehman, LG ;
Lell, B ;
Luckner, D ;
Schmidt-Ott, R ;
Kremsner, PG .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (06) :1584-1586
[17]   DNA vaccines: Immunology, application, and optimization [J].
Gurunathan, S ;
Klinman, DM ;
Seder, RA .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :927-974
[18]  
Gurunathan S, 1998, J IMMUNOL, V161, P4563
[19]   Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major [J].
Gurunathan, S ;
Sacks, DL ;
Brown, DR ;
Reiner, SL ;
Charest, H ;
Glaichenhaus, N ;
Seder, RA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1137-1147
[20]  
Hirunpetcharat C, 1999, J IMMUNOL, V162, P7309